Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice by Garriga-Canut, M et al.
	   1	  
Classification:  
Major category: Biological Sciences 
Minor Category: Neuroscience 
 
 
Synthetic zinc finger repressors reduce mutant 
Huntingtin expression in the brain of R6/2 mice 
 
Mireia Garriga-Canuta,2, Carmen Agustín-Pavóna,b,2, Frank Herrmanna, Aurora 
Sánchezc, Mara Dierssenb, Cristina Fillatd and Mark Isalana,1 
 
Proceedings of the National Academy of Sciences of the United 
States of America, 109(45), 2012 DOI: 10.1073/pnas.1206506109 
 
 
aEMBL/CRG Systems Biology Research Unit, and bGenes and Disease Programme, 
Centre for Genomic Regulation (CRG) and UPF, Dr. Aiguader 88, 08003 Barcelona, 
Spain. 
cServei de Bioquímica i Genètica Molecular, Hospital Clínic, 08028 Barcelona, Spain. 
dInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de 
Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona 
 
1Corresponding author: Mark Isalan, EMBL/CRG Systems Biology Research Unit, 
Centre for Genomic Regulation (CRG) and UPF, Dr. Aiguader 88, 08003 Barcelona, 
Spain. Telephone number: +34 93 316 0158. Email: mark.isalan@crg.eu. 	  
2These authors contributed equally to this work.	  




Huntington’s disease (HD) is a dominantly-inherited neurodegenerative disorder 
caused by expanded CAG repeats in the huntingtin (HTT) gene. Although several 
palliative treatments are available, there is currently no cure and patients generally die 
10 to 15 years after diagnosis. Several promising approaches for HD-therapy are 
currently in development, including RNAi and antisense analogues. We developed a 
complementary strategy to test repression of mutant HTT with zinc finger proteins 
(ZFP) in an HD model. We tested a 'molecular tape measure' approach, using long 
artificial ZFP chains, designed to bind longer CAG repeats more strongly than shorter 
repeats. After optimisation, stable ZFP expression in a model HD cell line reduced 
chromosomal expression of the mutant gene at both the protein and mRNA level 
(95% and 78% reduction, respectively). This was achieved chromosomally in the 
context of endogenous mouse HTT genes, with variable CAG repeat-lengths. Shorter 
wild-type alleles, other genomic CAG-repeat genes, and neighbouring genes were 
unaffected. In vivo, striatal AAV viral delivery in R6/2 mice was efficient and 
revealed dose-dependent repression of mutant HTT in the brain (up to 60%). 
Furthermore, zinc finger repression was tested at several levels, resulting in protein 
aggregate reduction, reduced decline in rotarod performance, and alleviation of 
clasping in R6/2 mice, establishing a proof-of-principle for synthetic transcription 
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Introduction 
The pathological expansion of CAG repeats leads to extended polyglutamine (polyQ) 
tracts in mutated gene products (1). The resulting proteins are thought to aggregate 
and cause toxic gain-of-function diseases, including spinocerebellar ataxias, 
spinobulbar muscular atrophy and Huntington’s disease (HD) (2, 3). HD 
neuropathology is associated with selective neuronal cell death, primarily of medium 
spiny neurons of the striatum and, to a lesser extent, cortical neurons, causing 
cognitive dysfunction and chorea (1, 4). Since the discovery, in 1993, that the 
huntingtin (HTT) gene caused HD (5), much attention has been focused on how the 
CAG-repeat number affects the pathology and progression of the disease; normally, 
the number of CAG repeats in the wild-type (wt) HTT gene ranges from 10 to 29 
(median 18) (1, 4), whereas HD patients typically range from 36 to 121 (median 44) 
(1, 4). Because the age of onset of disease is correlated to CAG repeat number (1), 
reducing the polyQ 'load' on cells should be beneficial therapeutically. 
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Despite intense research, there is no way to stop or delay the progression of HD and 
current treatments merely treat symptoms (1, 4). However, a number of promising 
studies have aimed at improving cell survival of affected areas (reviewed in (6)). 
Unlike other neurological disorders, such as Alzheimer’s and Parkinson’s diseases, 
HD is monogenic (5). Therefore, therapeutic strategies need only target the expression 
of the causal gene, to reverse and treat the effects of the mutant protein. However, 
since wt HTT protein is widely expressed (7), is essential for early embryonic 
development (8) and is required for neuronal function and survival in the brain (9), it 
is important to specifically reduce the expression of the mutant protein, while leaving 
the expression of the wt protein as unaffected as possible.  
 
Several approaches using synthetic nucleic acids that selectively target the mutant 
allele are currently being developed (reviewed in (10)). Recently, RNA interference 
(RNAi) was shown to reduce expression of mutant HTT (11-13). Although this 
technique could be very powerful, mutant-selective RNAi depends on targeting single 
nucleotide or deletion polymorphisms that differentiate between alleles, and these 
often differ from patient to patient. However, there is evidence that partial repression 
of wt HTT can be tolerated (14, 15), suggesting that generic approaches that repress 
both alleles should also be pursued. Peptide and locked nucleic acids (PNAs and 
LNAs) are generic and yet some promising partially-selective inhibition of expanded 
CAG repeats of the ataxin-3 and HTT genes has been reported (16, 17). Recently, 
there has even been sustained disease reversal using antisense oligonucleotides (18).  
 
Also aiming to reduce the levels of mutant protein, a different approach was proposed 
by Bauer et al. who designed a polyglutamine-binding peptide, fused to heat shock 
cognate protein 70 binding motif, to direct degradation of mutant HTT via chaperone-
mediated autophagy (19). Intrastriatal recombinant adeno-associated virus (rAAV) 
delivery of this fusion protein showed a strong therapeutic effect. 
 
In this study, we examined the use of zinc finger proteins (ZFP) as a complementary 
approach to reduce the expression of mutant HTT, which could be used in tandem 
with any of the above approaches. Because zinc fingers can be readily re-engineered 
to bind different DNA sequences (20-29), including CAG-repeats (30), they could in 
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principle be used to target the HTT gene at a transcriptional level. Furthermore, zinc 
fingers can be easily concatenated into long chains, and different linker designs can 
alter the interaction kinetics substantially (31). This suggested to us that a systematic 
appraisal of different-length ZFP, with appropriate linker designs, might reveal an 
optimal configuration for repressing mutant HTT, while leaving the wt allele 
relatively unaffected.  
 
We therefore designed a ZFP able to recognize and bind poly-5'-GC (A/T)-3', such 
that it would recognize both poly-CAG and its complementary DNA strand. The 
resulting ZFP chains (from 4- to 18-fingers) were able to repress target genes with 
longer CAG repeats preferentially, when compared to shorter repeats. This was 
carried out both in transient transfection reporter assays and with stable expression for 
20 days, against full HTT chromosomal targets, in various model cell lines for HD. 
Ultimately, we tested the most effective ZFP in vivo in the R6/2 HD mouse model, 
using AAV for delivery, establishing a proof-of-principle for gene repression by 
synthetic zinc fingers in the brain.  
 
Results 
Designing long ZFP chains to bind expanded CAG repeats. Zinc fingers can be 
concatenated to make long multi-finger chains (31, 32) and, to date, no one has 
systematically explored the binding modes of different-length ZFP to long repetitive 
DNA tracts. We therefore used rational design to construct a zinc finger (ZFxHunt) 
that would bind 5'-GC (A/T)-3', such that poly-finger proteins would bind poly-GCA 
and poly-GCT (see Methods; Fig. 1). Both DNA strands were targeted to increase the 
avidity for low-copy chromosomal targets. For structural reasons, zinc finger chains 
with canonical linkers lose their register with cognate DNA after 3 fingers. Therefore, 
extra -Gly (31) or 29-residue linkers were added after every 2- and 6-fingers, 
respectively (full sequences given in SI). In this way, different numbers of fingers 
could be tested for length-dependent discrimination. 
 
First, zinc finger chains containing either 4, 6 or 12 ZFxHunt domains were 
constructed and tested in gel shift assays, for binding to double-stranded CAG probes; 
longer ZFPs gave more complete binding (Fig. 1B). Intriguingly, distinct bound 
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complexes were observed, indicating that the ZFPs found single thermodynamic 
equilibria and were not trapped by kinetic intermediates. Highly-repetitive zinc 
fingers and DNA might have been expected to form contiguous partial binding events, 
which would have resulted in broad smears in gel shifts; this is not the case. 
Nonetheless, the 12-finger ZFP did give a lower, secondary shift, presumably caused 
by a 6-finger degradation by-product (zinc fingers can be unstable in linker regions 
(33)). To our knowledge, these 12-finger (and subsequently 18-finger) domains are 
the longest functional artificial ZFP chains ever built.  
 
To test whether ZFxHunt proteins are able to bind both strands of a CAG DNA probe, 
ZF6xHunt was assayed by gel shift, and was shown to bind equally to both a CAG 
repetitive probe, (GCA)x6, and to an alternate CAG-CTG probe, (GCA-GCT)x3 (Fig. 
1C). Furthermore, when compared to mutated sequences, ZF6xHunt showed 
specificity for (CAG)x7 (Fig. 1D). In summary, we built multi-finger ZFP able to bind 
poly 5'-GC (A/T)-3' DNA probes specifically and efficiently in vitro.  
 
Repression of polyQ reporter genes. Our starting hypothesis was that zinc finger 
proteins could preferentially bind longer CAG repeats through a mass action 
mechanism. Longer CAG repeats contain more target sites, and so should be bound 
and repressed more at any given ZFP concentration. Similarly, longer ZFP chains 
should also have a higher affinity, allowing one to balance expression, repression and 
length-preference. Although plasmid-based assays ultimately have different mass 
action kinetics to single-copy target chromosomal assays, they allowed us to verify 
our hypothesis rapidly before moving onto chromosomal targets.  
 
ZFxHunt of different lengths were therefore tested using reporter vectors with N-
terminal CAG repeats from the human HTT gene in frame with EGFP (Q0, Q10, Q35 
and Q104; Q=CAG). To assess non-specific effects, an HcRed reporter was cloned in 
a different region of the same vector, under an independent promoter (Fig. 2A). 
HEK293T cells were transiently co-transfected with the indicated reporter and 
ZFxHunt vectors, driven by CMV promoters. As gene therapy delivery vectors (used 
later) have a limited packaging capacity, which is exceeded by 12-fingers, we also 
tested an 11-finger construct. We found a similar expression levels and activity 
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between ZF12xHunt and ZF11xHunt (Fig. S1), and so used ZF11xHunt in all 
subsequent assays.  
 
Three assays were used to measure ZFxHunt repression: quantifying EGFP and 
HcRed fluorescent cells using Fluorescence-Activated Cell Sorting (FACS), EGFP 
protein levels in Western blots, and EGFP and HcRed mRNA levels in qRT-PCR 
(Fig. 2B-D). In these experiments, ZFxHunt with 6-, 11- and 18- fingers all repressed 
the two longer CAG-repeats strongly (5-9-fold: 80-90% repression) whereas 
ZF4xHunt was slightly weaker (2-4-fold: 50-75% repression). A Student’s t-test 
analysis revealed that ZF11xHunt gave significant repression of longer polyQ reporter 
genes the most consistently out of all ZF constructs, with no significant unspecific 
repression of the HcRed controls (p-values in Supplementary Tables S1,2). Verifying 
that the results were not specific to ZFP under the CMV promoter, similar results 
were obtained with the phosphoglycerate kinase (PGK) promoter (Fig. S2). Although 
binding interactions (and thus particular length-preference) can always be modulated 
by changing the effective concentration of each species, the main conclusion that can 
be drawn here is that there is a positive relationship between CAG repeat number and 
repression level. Furthermore, ZF6-, ZF11- and ZF18xHunt are all strong repressors 
of longer repeats under these conditions.  
 
Competition assays show preferential repression of long CAG-repeats by 
ZFxHunt. Up to this point, the zinc fingers had displayed length preference for single 
CAG-repeat targets in cells. Another test of potential length-preference is for 
discrimination against two targets per cell, each with a different number of CAG-
repeats. HEK293T cells were therefore co-transfected with three plasmids: the 
indicated polyQ-EGFP and polyQ-mCherry reporter vectors, together with various 
ZFxHunt vectors (Fig. 3). The relative expression of the two reporters was measured 
by FACS (EGFP or mCherry positive cells). Figure 3 shows that the longer CAG-
repeats are preferentially repressed by all ZFxHunt, so that cells are dominated by the 
shorter green or red constructs when their opposite counterpart is longer; this is seen 
directly by looking at the ratio of green-to-red expression. This can be explained most 
simply by mass action (longer CAG-repeats contain more target sites, so are bound 
and repressed more).  
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This assay demonstrates the potential of ZFxHunt for CAG-length discrimination. 
Therefore length preference exists, even for multiple different-length CAG-repeats 
within the same cell. The remaining caveat is that the system still needs to be tailored 
(expression levels, zinc finger length, repression strength) for the particular cellular 
environment. We therefore moved next to testing in a more physiological 
chromosomal cellular environment. 
 
Chromosomal repression of mutant HTT in a HD model cell line. Since ZF4xHunt 
had weaker binding and length preference (Fig. 2, 3), and since ZF12- and 
ZF18xHunt are beyond the packaging limit of AAV, we focussed on testing 
ZF6xHunt and ZF11xHunt, on chromosomal HTT genes. STHdh cells (34) are an 
established neuronal progenitor cell line from E14 striatal primordia, derived from wt 
mice (STHdhQ7/HdhQ7), or knock-ins, where the first exon of the mouse HTT gene has 
been replaced by a human exon with 111 CAG repeats (STHdhQ111/HdhQ111 or 
STHdhQ7/HdhQ111). Because the chromosomal targets are present at a much lower 
effective concentration, to increase the repression per binding event we also tested an 
effector domain in parallel: the Kox-1 KRAB domain (35).  
 
STHdh cells stably expressing 'naked' or Kox-1-fused ZF6xHunt and ZF11xHunt 
were harvested 20 days after retroviral infection, and huntingtin levels were analyzed 
by Western blot and qRT-PCR (Fig. 4A). Neither protein nor RNA levels of wt HTT 
(Q7) were reduced by naked or Kox-1-fused ZF6xHunt and ZF11xHunt. By contrast, 
Q111-mutant HTT RNA and protein levels were repressed with ZF6xHunt-Kox-1 by 
up to 2.5-fold (60% reduction) and 2-fold (50% reduction), respectively. Similar 
results were achieved in Q7/Q111 heterozygous cells (Fig. S3). ZF11xHunt-Kox-1 
showed even stronger repression, with almost 80% reduction in mRNA expression 
and 95% reduction in the protein levels. Overall, the longer 11-finger construct, 
together with stronger Kox-1 repression, displayed the strongest chromosomal 
repression of mut HTT.  
 
ZFxHunt does not repress wt CAG-containing genes. Genomes contain several 
other endogenous CAG repeat genes, and so the potential side-effects of stably-
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expressed ZFxHunt proteins were assayed by qRT-PCR for atrophin1, ataxin-1, 
ataxin-2, ataxin-3, ataxin-7, calcium channel alpha 1A subunit, and TATA binding 
protein (Fig. 4B-D). No strong effects were seen in either STHdh mouse cells (Fig. 
4B), or in HEK293T cells (with counterpart human PCR primers)(Fig. 4C). In the 
latter, even genes with relatively long repeats were unaffected (human HTT, 21-
repeats; Tbp ~38-repeats: 36 CAG repeats broken by two non consecutive CAA 
codons; Table S3). 
 
As Kox-1 recruits the co-repressor KAP-1 and induces long-range repression through 
the spread of heterochromatin (36), we tested the effects of ZF6xHunt-Kox-1 and 
ZF11xHunt-Kox-1 on genes neighboring HTT, in stably-transduced STHdh cells, by 
qRT-PCR (Fig. 4B). The two adjacent genes, G protein-coupled receptor kinase 4 (~7 
kb upstream) and G-protein signaling 12 (~188 kb downstream), were both 
unchanged, suggesting that they are out of range. Thus, ZF6- and ZF11xHunt-Kox-1 
repression appears to be specific for mutant HTT in chromosomal loci. Additionally, a 
dye-labeling cell viability assay (Fig. S4) revealed no statistically significant toxic 
effects, encouraging us to test the ZFP's potential in vivo.  
 
ZF11xHunt-KoxI represses HTT in a HD patient cell line. Since HD patients 
typically have CAG-repeats in the 42-45 range, we tested the potential for repression 
of these shorter targets in a patient-derived mesothelial cell line (Q45/Q21). We again 
observed that other genomic CAG-repeat genes remained unaffected, while HTT was 
repressed (Fig. 4D). The Q45/Q21 line is heterozygous and, based on the other 
repression data, we only expect the Q45 allele to be repressed under these conditions. 
100% repression of only the mutant allele would give a maximum 2-fold repression of 
HTT in this assay. In fact we observe a ~1.8-fold repression of HTT (Fig. 4D). As the 
other shorter CAG-repeat genes (including the split 38-repeat Tbp) are not repressed, 
this indicates that selective inhibition of mutant repeats at the shorter end of the 
pathological spectrum is possible. 
 
ZFxHunt fused to Kox-1 reduces expression of mutant HTT in vivo. Although 
ZF11xHunt-Kox-1 apparently functioned well in the stable transfection with dividing 
cells, this system is quite different from the environment of a mammalian brain, 
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where there are many cell types and most of them are non-dividing. We therefore 
decided to test whether any repression could be observed in a more physiological 
setting.  
 
rAAV pseudotype 2/1 (AAV2/1), containing AAV2 terminal repeats and AAV1 
capsid, efficiently transduces neurons (and most glial and some ependymal cells) and 
appears to be the most efficient pseudotype for transducing large volumes of the 
striatum (37). R6/2 mice are one of the most-widely used models of HD because they 
show highly reproducible early onset symptoms, allowing the use of fewer animals 
(38). Although R6/2 have very long CAG-repeats (range 115-160), which are rarely 
found in patients (typically in the 42-45 range), they are nonetheless ideal to assay 
acute phenotypic reversal at the molecular, histologic and early-symptom levels (39). 
Therefore, R6/2 mice were stereotaxically injected at 4 weeks of age with AAV2/1 
expressing ZF11xHunt-Kox-1.  
 
We initially tested vectors expressing the ZF under a CMV promoter, but we 
observed very low levels of expression of the ZF protein and mRNA, and no 
repression of mutant HTT. CMV promoters can be quickly silenced by DNA 
methylation (40), whereas high and persistent levels of expression can be achieved in 
the central nervous system with rAAV using the CAG promoter (CMV enhancer, 
chicken beta-actin hybrid promoter) and a WPRE (Woodchuck hepatitis virus 
postranscriptional regulatory element) (41, 42). We therefore produced a second 
generation of rAAV using these elements.  
 
CAG-WPRE constructs were injected into the striatum of one brain hemisphere, with 
AAV2/1-GFP control injections (equal titre) into the other. ZFP striatal expression 
was confirmed by Western blot (Fig. S5A), while GFP fluorescence shows 
transduction of large striatal volumes (Fig. 5A). For parallel behavioural studies, both 
hemispheres were injected (Fig. 5B), also resulting in high and reproducible 
expression (Fig. 5C). The cellular targeting of AAV2/1 was assayed by 
immunohistochemistry, showing that transgene expression coincides with a neuronal 
cell marker as previously shown in Ref. (37) (Fig. S6CDE).  
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Two weeks after injection, the mice were sacrificed and brain HTT levels were 
analysed by qRT-PCR (Fig. 6A,B). The levels of mutant HTT transgene mRNA were 
reduced in the striatum by 40% on average (up to 60% in individual mice), as 
compared to the control hemispheres (p = 0.006). Furthermore, both the non-injected 
cerebellum and wt HTT were unaffected (Fig. 6A). A linear regression analysis, 
comparing expression levels of ZFxHunt-Kox-1 mRNA with those of mutant HTT, 
showed that they correlated closely and negatively (r = 0.83; p = 0.02) (Fig. 6B). 
Aggregates of mutant HTT protein were detected with anti-HTT antibodies (Fig. 6C), 
also showing a significant reduction (~40%) in the treated striatum (Fig. 6D; 
Student’s t test for paired samples, p=0.03; Fig. S7, S8). Again, mutant HTT did not 
change significantly in the non-injected cortex (Fig. 6C,D).  
 
Neither striatal volume nor cell density in the striatum was affected by treatment or 
genotype, indicating that the reduction of mutant HTT was not due to a loss of cells 
and providing no evidence of ZFxHunt toxicity at this level (ANOVA, Genotype 
p>0.1; Treatment p>0.1)(Table S4). Overall, these data are consistent with in vivo 
dose-dependent repression of mutant HTT by the zinc finger construct.  
 
The results demonstrate acute mutant HTT repression by zinc fingers in the mouse 
brain. Therefore, we tested in vivo if the molecular changes observed in the brain 
would translate to beneficial effects on the pathology phenotype of the R6/2 HD 
mouse model. 
 
First, we investigated whether the zinc finger repression improved the HD phenotype, 
using a standard assay where HD-mice display a clasping behaviour when lifted by 
the tail (43) (Fig. 7A). In a double blind experiment, male R6/2 mice were injected 
bilaterally in the striata, at 4 weeks of age, with AAV2/1-ZF11xHunt-Kox-1 or 
AAV2/1-GFP. A control group was left un-operated. Strikingly, the AAV2/1-
ZF11xHunt-Kox-1 injected mice showed an almost complete absence of diseased 
clasping behaviour (Fig. 7B). While control R6/2 mice started displaying clasping as 
early as week 4, ZF-treated R6/2 mice did not clasp until week 7. Even then, only 1/8 
ZF-treated mice clasped, compared to 6/12 control R6/2 mice (Chi-square test, 
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p=0.03). GFP-treated R6/2 mice did not differ from un-operated controls (p > 
0.7)(Fig. 7B).  
 
To assess motor coordination, male R6/2 mice and their wt littermates were tested at 3 
weeks of age for their baseline performance (latency to fall) in the accelerating 
rotarod test. They subsequently received bilateral striatal injections at 4 weeks, as 
described above. Repeated measures ANOVA comparing the decline in R6/2 
performance revealed that GFP-treated R6/2 were significantly impaired as compared 
to their GFP-treated wt controls (p=0.035), whereas the AAV2/1-ZF11xHunt-Kox-1 
treated R6/2 mice not different from the wt mice (p>0.1)(Fig. 7C).  
 
In our experiments, R6/2 mice do not experience any weight-loss or changes in 
survival compared to their wt counterparts and thus these phenotypes cannot be used 
as endpoints. We did not observe any significant difference in weight between wt and 
R6/2, treated and untreated mice (Fig. S9) and no mice died during the experiment, 
either with or without treatment, so no conclusion can be drawn about the effect of 
treatment on these phenotypes. 
 
The data presented establish a proof-of-principle that zinc finger repressors can be 
active after striatal delivery, with HTT reduction at the RNA and protein level, and 
significant improvements in disease phenotypes in a HD mouse model. 
 
Discussion 
In this study, we have described the design of a ZFP able to recognize and bind both 
DNA strands of a stretch of CAG repeats, by recognizing both poly-GCA and -GCT 
triplets, to induce transcription repression. As shown in Figure 2, even naked 
ZFxHunt are highly efficient episomally and can reduce polyQ-EGFP expression by 
up to 90%. The mechanism of repression here is likely to be steric hindrance of RNA 
polymerase complex progression, as reported by Choo et al. for a synthetic ZFP 
against the bcr-abl oncogene (44). By contrast, in chromosomal loci, the stronger 
repression conferred by the Kox-I repression domain (35, 36) is required to see an 
effect (Figure 4).  
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One major in vitro observation was that longer CAG-repeats were repressed more by 
particular finger constructs under given conditions, suggesting that mass action can be 
exploited to give a degree of length preference. Binding to different lengths of CAG-
repeats is, of course, altered by the effective concentrations of both zinc finger and 
target. We therefore had to find empirically which length of zinc finger and which 
expression construct would give an effective dose to discriminate between the lengths 
of CAG-repeats in a chosen HD mouse model.  
 
By first using a model cell line derived from striatial cells of a knock-in HD mouse 
model (the full HTT gene, with variable CAG-repeats in exon 1) (34), we found 
effective constructs and doses which gave a great deal of specificity for repressing 
mutant Huntingtin at a chromosomal level. Although repression of the shorter wt HTT 
protein is well tolerated for several months in animal models (14, 45), it is desirable to 
preferentially target the mutant allele (13, 16), and one should not affect other CAG-
repeat containing genes. In fact, under the dosages tested, we found conditions in 
which mutant HTT was strongly repressed for a sustained period of 20 days, with no 
apparent side-effects on other shorter CAG-repeat genes. Therefore the next step was 
to explore whether repression could also be achieved in the brain, using gene therapy 
vectors for delivery. 
 
Gene therapy is an attractive therapeutic strategy for various neurodegenerative 
diseases. For example, lentiviral vectors have been used to mediate the widespread 
and long-term expression of transgenes in non dividing cells such as mature neurons 
(46). A rAAV vector was also used by Rodriguez-Lebron et al. (47) to deliver anti-
mutant HTT shRNAs in HD model mice, thereby reducing striatal mutant HTT levels 
and slowing progression of the HD-like phenotype. As outlined in the introduction, 
several strategies to target HTT have shown promise (11-13, 16, 17, 19). However, 
repression in the brain by a synthetic transcription factor has never been reported. It 
was unknown whether sufficient levels of protein could be produced after in vivo 
delivery to see any repression, whether transcription repression would be sufficient to 
reduce protein levels, and whether such constructs would show acute toxicity. In fact, 
we were able to get effective repressors that were well-tolerated, but this required a 
degree of further optimisation, including the use of a strong CAG promoter and 
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WPRE (42). With these improvements we observed selective repression of mutant 
HTT RNA, a reduction in HTT protein aggregates and an alleviation of associated HD 
phenotypic deficits. 
 
Overall, the results presented in this study establish a proof-of-principle that ZFs can 
acutely repress mutant HTT in vivo via striatal injection, in a dose-dependent manner. 
These results imply that it is worth pursuing these constructs to test a multitude of 
possible gene therapy vector and zinc finger variants, with a view to optimising 
potential therapeutic benefit.  
 
 
Materials and Methods 
 
Vectors. To build a ZFP that recognizes both GCA and GCT DNA sequences, we 
based our designs on two previous studies. Choo et al. (44) engineered ZFPs with the 
following alpha-helical recognition sequences: QAATLQR for GCA, and QAQTLQR 
for GCT. Isalan et al. (48), showed that QRASRKR recognizes GN (T/A). Therefore 
we proposed a hybrid design, QRATLQR (ZFxHunt), for GC (T/A) (Fig. 1c). A 
pUC56 vector containing ZF6xHunt was synthesised by	  Genscript Corporation 
(Piscataway, NJ). This vector included a T7 promoter, zif268 DNA-binding domain 
backbone, an N-terminal NLS (PKKKRKV), and restriction sites for deriving ZF4, 12 
and 18 by subcloning (full sequences given in Supplementary Information). 
 
ZF6xHunt was subcloned into the mammalian expression vector pTarget (Promega). 
A 3xFLAG tag sequence (DYKDHDG DYKDHDI DYKDDDDK) was introduced by 
PCR at the N-terminus, and either FokI endonuclease domain or Kox-1 (KRAB 
repression domain) coding sequences were introduced at the C-terminus, with a 
3xGGGGS linker. 
 
The pEH vector series was cloned in two steps. First, EGFP coding region was 
excised from pEGFP-N1 (Clontech), using HindIII/XbaI, and cloned into pGL4.13 
(Promega) to give pSV40-EGFP. Then, a PCR product containing CMV-HcRed-
polyA and ClaI linkers was cloned into pSV40-EGFP (partially digested with ClaI). 
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The EGFP start codon was mutated to Alanine by site directed mutagenesis, and PCR 
fragments containing human HTT exon I from different human genomic templates (to 
obtain different number of CAG repeats) were cloned into the pEH EcoRI site, 
upstream and in frame with EGFP (pEH-Q series). The pSV40-mCherry vector series 
were generated by replacing EGFP from the pSV40-EGFP vector series by mCherry 
using XmaI/XbaI sites.  
 
Gel Shift. pUC56-ZFxHunt and M13 and M13rev primers were used to generate PCR 
products for in vitro expression of the indicated ZFP, using the TNT T7 Quick PCR 
DNA kit (Promega). Double stranded DNA probes with different number of CAG 
repeats with the standard sequence ACG TAC (CAG)x TCA CAG TCA GTC CAC 
ACG TC were produced by Klenow fill-in. 100 ng of double stranded DNA were 
used in a DIG-labeling reaction using Gel Shift kit, 2nd generation (Roche) following 
manufacturer’s instructions. For gel shift assays, 0.005 pmol of DIG-labelled probe 
were incubated with increasing amounts of TNT-expressed protein in a 20 µl reaction 
containing 0.1 mg/ml BSA, 0.1 µg/ml polydI:dC, 5% glycerol, 20 mM Bis-Tris 
Propane, 100 mM NaCl, 5 mM MgCl2, 50 mg/ml ZnCl2, 0.1% NonidetP40 and 5 mM 
DTT for 1 h at 25˚C. Binding reactions were separated in a 7% non-denaturing 
acrylamide gel for 1 h at 100 V, transferred to a nylon membrane for 30 min at 400 
mA, and visualization was performed following manufacturer’s instructions.  
 
Cell culture and gene delivery. The cell line HEK293T (ATCC) was cultured in 5% 
CO2 at 37˚C in DMEM (Gibco) supplemented with 10% FBS (Gibco). Qiagen 
purified DNA was transfected into cells using Lipofectamine 2000 (Invitrogen) 
according to manufacturer’s instructions. Briefly, cells were plated onto 10 mm wells 
to a density of 50% and 70 ng of reporter plasmid, 330 ng of ZFP expression plasmid 
and 2 µl of Lipofectamine 2000 were mixed and added to the cells. Cells were 
harvested for analysis 48 hours later. All assays were performed in triplicate. 
STHdh+/Hdh+ and STHdhQ111/Hdh111 cells (gift from M.E. MacDonald) were 
cultured in 5% CO2 at 33˚C in DMEM supplemented with 10% FBS (Gibco) and 400 
µg/ml G418 (PAA). Q45/Q21 patient-derived cell line: mesothelial cells from a 
heterozygous HD patient (Q45/Q21) were collected from urine and cryopreserved 
with glycerol. After thawing, surviving cells were grown in Chang Medium D. Cells 
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were infected with retroviral particles using the pRetroX system (Clontech) according 
to manufacturer’s instructions. Samples were FACS sorted for GFP expression 7 days 
after transduction, and allowed to recover for 2 weeks before extracting RNA or 
protein for qRT-PCR and Western blot.  
 
Flow cytometry analysis. Cells were harvested 48 h post-transfection and analyzed 
in a BD FACS Canto Flow cytometer using BD FACSDiva software.  
 
Western blot. 293T cells were harvested 48 hours post-transfection in 100 µl of 
2xSDS loading dye with Complete protease inhibitor (Roche). 20µl of sample were 
separated in 4-15% Criterion Tris-HCl ready gels (BioRad) for 2 h at 100V, 
transferred to Hybond-C membrane (GE Healthcare) for 1 h at 100V. Proteins were 
detected with either the primary antibody anti β-actin (Sigma A1978) at 1:3 000 
dilution or Anti-EGFP (Roche) at 1:1,500 dilution and with a Peroxidase-conjugated 
Donkey anti-mouse secondary antibody (Jackson ImmunoResearch) at 1:10 000 
dilution. Visualization was performed with ECL system (GE Healthcare) using a 
LAS-3000 imaging system (Fujifilm). STHdh cells (from one ~80% confluent 15 cm 
plate) were trypsinized and harvested in PBS containing Complete protease inhibitor 
(Roche). Cells were resuspended in RIPA buffer (1% TritonX-100, 1% sodium 
deoxycholate, 40 mM Tris-HCl, 150 mM NaCl, 0.2% SDS, Complete), incubated in 
ice for 15 min, and were centrifuged at 13.000 rpm for 15 min. The supernatant was 
collected and protein concentration was determined using BioRad’s DC protein assay. 
60 µg of protein were separated in a 5% Criterion Tris-HCl ready gel (BioRad) for 2 
hours at 100V, transferred using iBlot Dry Blotting System (Invitrogen) for 8 min and 
endogenous HTT protein was detected with anti-Huntingtin primary antibody 
(Millipore MAB2166) at a 1:1 000 dilution.  
 
qRT-PCR. RNA from cells in one well of an ~80% confluent 24-well plate was 
prepared with RNeasy kit (Qiagen) and 500ng (unless indicated) were reversed 
transcribed with Superscript II (Invitrogen). Real Time PCR was performed in a 
LightCycler® 480 Instrument (Roche) using LightCycler® 480 SYBR Green I Master 
(Roche). SYBR Advantage GC qPCR Premix (Clontech) was used to amplify the 
human HTT transgene in R6/2 templates. For technical replicates, each PCR was done 
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in triplicate, and results normalized to three housekeeping genes. At least 3 
independent biological replicates (or as indicated if different) were done for each 
experiment. Primer sets are given in full in Table S3.  
 
Production of Adeno-Associated Viral Vector. AAV2/1-CAG-GFP-WPRE and 
AAV2/1-CAG-ZF11xHunt-KoxI-WPRE, containing a CAG promoter (CMV early 
enhancer element and the chicken beta-actin promoter) and WPRE (Woodchuck post-
translational regulatory element) were produced at the Centre for Animal 
Biotechnology and Gene Therapy of the Universitat Autonoma of Barcelona 
(CBATEG-UAB) as previously described (49). Recombinant virus was purified by 
precipitation with PEG8000 followed by iodixanol gradient ultracentrifugation with a 
final titer of 7.41 × 1011 genome copies/ml. 
 
Animals. R6/2 transgenic mice were purchased form Jackson Laboratories (B6CBA-
Tg(HDexon1)62Gpb/3J). Ovarian transplanted hemizygous females and wt 
B6CBAF1/J males were bred in house, and progeny was genotyped as previously 
described (50). Stereotaxic injections were performed on 4-week-old mice. Briefly, 
mice were anesthetized with a mix of ketamine (75 mg/kg) and medetomidine (1 
mg/kg, i.p.) and fixed on a stereotaxic frame. Analgesia was provided by 
buprenorphine (8 µg/kg, s.c.). AAVs were injected bilaterally into the striatum (A/P 
+0.7 mm, M/L ± 1.8 mm, D/V −3.0 mm relative to bregma) using a 10 μl Hamilton 
syringe at a rate of 0.25 μl/min controlled by an Ultramicropump (World Precision 
Instruments). For each hemisphere, a total volume of 3 µl (2.2x109 genomic particles) 
were injected in two steps: 1.5 μl were injected at −3.0 mm DV, the needle was let to 
stand for 3 minutes in position, and then the other half was injected at −2.5 mm DV. 
Mice were randomly injected with AAV2/1-CAG-ZF11xHunt-Kox-1-WPRE in one 
hemisphere and with control AAV expressing GFP into the other hemisphere. Some 
mice were injected only in one hemisphere with AAV2/1-ZF for comparison to non-
injected control hemisphere.  Mice were sacrificed after 2 weeks for posterior analysis 
by RT-PCR (primers: mut HTT, n=6; wt HTT, n=9; ZF-Kox, n=9) and histological 
analyses (WT, n=3; R6/2, n=3).  
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Histology. Mice were killed with CO2 and rapidly transcardially perfused with saline 
solution, followed by 75 ml of 4% paraformaldehyde in 0.01 M phosphate-buffered 
saline (PBS). Hemispheres were separated and post-fixed in the same fixative o.n. at 
4ºC and immersed in 30% sucrose-PBS until they sank. Hemibrains were frozen in a 
freezing microtome cryostat and 40 µm-thick coronal sections were obtained. 
Freefloating sections were collected in six parallel series. One section was stained 
with Hematoxilin-eosin for calculation of the volume of the striatum in both R6/2 and 
WT mice. A second section was processed for immunocytochemical detection of 
human mutant huntingtin. As controls, we used a mix of slices from wt mice 
following the whole immunodetection, as well as one slice per hemisphere and R6/2 
mouse not incubated with the primary antibody. The rest of the series were frozen in 
cryoprotectant solution for further use. 
 
Briefly, sections were incubated sequentially in: (i) 1% hydrogen peroxide (H2O2) in 
TBS for 30 min at room temperature, for endogenous peroxidase inactivation; (ii) 
mouse anti-mut HTT (Millipore MAB5374) diluted 1 : 100 in TBS with 0.3% Triton 
X-100 (Sigma, St. Louis, MO, USA) and 2% normal goat serum (NGS, Vector 
Laboratories, Burlingame, CA, USA), overnight at 4 ºC; (iii) biotinylated goat anti-
mouse IgG (Vector Laboratories) diluted 1 : 200 in TBS with 0.3% Triton X-100 and 
2% NGS for 2 h at room temperature; and (iv) avidin–biotin–peroxidase complex 
(ABC Elite Kit; Vector Laboratories) in TBS with 0.3% Triton X-100, for 90 min at 
room temperature. Following each incubation, sections were washed in TBS (3x5 
min). The resulting peroxidase activity was revealed with FAST diaminobenzidine 
(Sigma) for 5 min. Sections were rinsed in TBS and mounted onto slides, cleared with 
xylene, and coverslips were fixed with Permount. For Neu-N detection, slices were (i) 
incubated o.n. at 4º with anti-neu-N (Millipore MAB377) (ii) goat-anti-mouse-Alexa-
555 (Invitrogen A21422).  
 
Image analysis 
Determination of the volume and cell density of the striatum. Striatal volume was 
determined using the software Computer Assisted Stereology Toolbox (CAST) 
(Olympus Danmark, A/S) according to the principle of Cavalieri 
(volume=s1d1+s2d2+….sndn) (51) considering 8 coronal levels from bregma 1.5 mm 
(following the mouse brain atlas (52)) and an interval of 240 µm between the 
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sections. Cell density was calculated in the same slices using the unbiased optical 
dissector method (53). 
Automatic count of mut HTT positive particles. In the mut HTT immunostained 
series, 4 coronal slices per R6/2 mouse and hemisphere from bregma 1.5 levels were 
selected, and a region of interest of 650 x 865 µm2 in the middle of dorsal striatum 
captured with a 10X objective using a digital camera attached to a Olympus BX51 
microscope. ImageJ software (NIH) was used for image analysis. Following the 
method of Ref. (52)(Fig. S7), counts were obtained and calculated per 0.1 mm2. This 
gave the number of mut HTT immunoreactive particles in the 4 slices of both cerebral 
hemispheres and the number of particles averaged providing a single density measure 
per mouse. 
 
Clasping assay. R6/2 males were bilaterally injected with 3 µl of the same virus in 
both hemispheres for behavioral assays. Behavioral monitoring was carried out from 
4 to 7 weeks of age. All the experiments were blindly performed with respect to the 
treatment of the mice (R6/2 mice: un-operated, n=8, ZFP-treated n=8; GFP-mock 
treated, n=4). Animals were assessed for clasping behaviour by suspending them by 
their tails for 20 seconds. Mice clasping their hindlimbs were given a score of 1 and 
mice that did not clasp, 0.  
 
Accelerating rotarod. Mice (R6/2 mice: ZFP-treated n=12; GFP-mock treated, n=12; 
WT mice: ZFP-treated n=14; GFP-mock treated, n=14) were trained at week 3 of age 
to stay on the rod at a constant speed of 4 r.p.m. until they reached a criterion of 3 
consecutive minutes on it. In the testing phase, mice were put in the rotarod at 4 r.pm. 
and the speed was constantly increased for 2 minutes to 40 r.p.m. The assay was 
repeated twice and the maximum latency to fall from the rod was recorded. Decline in 
performance was calculated as the difference in the latency to fall from pre-surgery 
levels with respect to weeks 5 and 7. 
 
Statistical analysis. Error bars in figures are one standard error based on at least three 
biological replicates. Data of the repression of polyQ reporter genes experiments were 
analysed using a Student’s t test against an expected value of 1 (no repression or 
activation). Expected percentages of mice clasping were inferred of our population of 
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un-operated R6/2 mice, and a Chi-square test for goodness-of-fit was applied to the 
observed percentages in operated groups. Data of the accelerating rotarod test were 
analyzed using repeated measures ANOVA with week as within-subject factor and 
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Figure Legends 
 
Figure 1. Zinc finger arrays to bind CAG-repeats. (A) A 12-finger array, showing 
recognition helices contacting 5'-GCT-3' bases on the lower DNA strand. Similar 
arrays of 4, 6, 12 or 18 zinc fingers were built (ZF4xHunt, ZF6xHunt, ZF12xHunt 
and ZF18xHunt). Nuclear localization signals (NLS) and effectors (e.g. Kox-1 
transcription repression domain) were added to N- and C- termini, respectively. (B) 
Gel shift assays show 4-, 6- or 12-finger arrays binding poly-CAG DNA and forming 
distinct complexes. Negative control: transcription-translation mix (TNT). (C) The 
hybrid zinc finger design recognizes 5'-GC(A/T)-3', allowing binding to either the 
(GCA)n or the (GCT)n complementary strands of the CAG-repeat. A gel shift assay 
shows equal binding to GCA or GCT triplets in mixed sequences. (D) Specificity gel 
shift assay. Zinc fingers bind preferentially to CAG repeats (CAG7) when compared 
to degenerate mutant sequences (DAG7, CSG7 or CAH7; D=A,G,T; S=C,G; 
H=A,C,T).   
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Figure 2. Episomal poly-CAG-reporter repression by ZFxHunt. (A) The pEH reporter 
plasmid contains EGFP, fused to the N-terminal CAG repeats of the human HTT 
gene, expressing different-length poly-Q coding sequences under an SV40 promoter. 
A control HcRed gene, under a CMV promoter, measures off-target or long-range 
repression. Key: ZFP expression constructs (0 - 18 fingers). (B) FACS assay 
measuring the fold-reduction in EGFP and HcRED fluorescent cells, in response to 
different zinc fingers. A 10-fold repression is equivalent to 90% reduction. Results are 
the mean +/- s.e.m of three independent experiments. (C) EGFP Western blot for ZFP 
repression of pEH-Qx targets. (D) qRT-PCR assay to measure fold-repression of 
EGFP or HcRED mRNA by ZFP. Results are the mean +/- s.e.m of four independent 
experiments.  	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Figure 3. ZFP competition assay against pairs of different-length CAG repeats. Each 
small square represents one transfection experiment, where cells simultaneously 
receive two reporter plasmids: poly-Q-EGFP and poly-Q-mCherry of different lengths 
(Q0 to Q104). ZFxHunt with 4-, 6-, 11- or 18-fingers were tested for their ability to 
reduce the number of detectable green and red cells in FACS assays (%). Longer 
poly-Q constructs are repressed preferentially, resulting in the shorter green or shorter 
red poly-Q constructs dominating expression.  
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Figure 4. Expression of chromosomal CAG-repeat genes, 20 days after retroviral ZFP 
delivery. Assays were carried out in wt mouse STHdh cells (Q7/Q7), in poly-Q 
STHdh mutants (Q111/Q111), and in human HEK293T, as indicated. Mouse and 
human genes are prefixed by "m" and "h", respectively. (A) Repression of 
endogenous HTT by ZF6xHunt and ZF11xHunt, with and without Kox-1 repressor 
domain. Western blots for HTT (top) were controlled with β-actin staining and 
quantified using ImageJ (Protein fold-repression; middle). qRT-PCR was used to 
compare HTT mRNA levels (RNA fold repression; bottom). The experiment was 
repeated independently three times with similar results; one experiment is displayed. 
(B) The mRNA levels of other wt CAG-repeat genes are broadly unaffected in STHdh 
cells (pooled samples: 3 Q7/Q7 and 3 Q111/Q111). 7 genes were tested by qRT-PCR 
(atrophin1: ATN1; ataxin-1-3,7: ATXN1-3,7; calcium channel alpha 1A subunit: 
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CACNA1A; TATA binding protein: TBP). CAG-repeat numbers are in brackets; The 
first number corresponds to pure CAG repeats, the second number to broken CAG 
repeats (containing CAA or CAT). Two genomic neighbours of HTT, (G protein-
coupled receptor kinase 4: GRK4, ~7 kb upstream; G-protein signaling 12: Rgs12, 
~188 kb downstream) were also unaffected in STHdh cells. (C) The mRNA levels of 
the 7 wt human CAG genes and HTT (huntingtin; 21 repeats) were also broadly 
unaffected in HEK293T cells. (D) ZF11xHunt-Kox-1 represses only HTT in a 
heterozygous human patient-derived cell line (mut Q45/wt Q21). RNA was extracted 
from FACS-sorted transduced cells, 7 days after infection. N.B. CACNA1A is not 
expressed in HEK293T or the Q45/Q21 patient cell line.  
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Figure 5. Gene delivery by stereotaxis. (A) A cross-section of mouse brain, injected 
in one hemisphere with AAV2/1-CAG-GFP-WPRE, reveals widespread green 
fluorescence in the striatum. (B) Similar distributions are seen when injecting the GFP 
construct in both hemispheres (as for the behavioural assay). The zinc finger construct 
AAV2/1-CAG-ZF11xHunt-Kox-1-WPRE was injected at identical titre, in one or 
both hemispheres, as described. (C) Schematic drawings showing the maximum and 
minimum volume covered by GFP expression in mice injected in both hemispheres 
(n=4). AP levels as in Paxinos and Watson atlas of the mouse brain. aca= anterior 
comissure; Acb=nucleus accumbens; lo=olfactory tract; St=striatum; Tu=olfactory 
tubercle.  
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Figure 6. ZF repression in vivo (A) qRT-PCR data quantifying mRNA levels in 
mouse samples injected striatally with ZF11xHunt-Kox-1, compared to the control 
hemisphere. Mutant HTT (mut HTT) is repressed ~40% by the zinc finger construct in 
the striatum, whereas it is unaffected in the non-injected cerebellum. Wild-type HTT 
(wt HTT) is unaffected in all samples. Mut HTT n=6; wt HTT n=9. Control groups 
contain both untreated and GFP-treated mice (the groups are similar; Fig. S6B). (B) 
Linear regression analysis of zinc finger expression (ZF11xHunt-Kox-1) versus mut 
HTT expression shows a significant negative correlation (p=0.02). Data are from the 
treated hemispheres (n=6) and the corresponding untreated hemispheres (mean +/- 
s.e.m.). (C) Anti-HTT immunostaining of brain samples reveals a reduction of mutant 
aggregates in injected striatum with ZF11xHunt-Kox-1 treatment. Scale bars: 100 µm. 
(D) Quantifying HTT-positive aggregates by automatic counting of mut HTT positive 
particles with ImageJ software, as previously described (52)(Fig. S7). The data are 
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from 3 mice and represent comparisons between their injected and non-injected 
hemispheres, in striatum and cortex.  
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Figure 7. Rescue of HD phenotypes with in vivo ZF treatment. (A) HD mice show a 
characteristic clasping behaviour (diseased) corresponding to neurological pathology 
(43). (B) The clasping assay shows a significant improvement after zinc finger 
treatment in both hemispheres (p=0.03). Only 1 in 8 ZF-treated mice display 
symptoms by week 7, compared with 6 in 12 control mice. (C) Performance in the 
accelerating rotarod shows a clear decline with respect to pre-surgery levels in the 
GFP-injected R6/2 mice, whereas ZF-treated mice do not show a significant decline 
as compared to WT mice.  
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The DNA and protein sequences of ZF6xHunt-Kox-1 and ZF12xHunt-Kox-1 
 
The following coding sequences were cloned into the pTarget plasmid (Promega), to 







NLS: nuclear localisation signal 
Zinc finger sequence, α-helices underlined in protein 
linker sequences in bold in protein 
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Supplementary Table S1. Students’ t-test analysis of the fold repression data against 
an expected value of 1, from the FACS experiment in Fig. 2B.  
 




p-­‐value	  ZF4xHunt	   Q0	   EGFP	   0.894	  	   Q10	   0.363	  	   Q35	   <0.001	  	   Q104	   <0.001	  	   Q0	   HcRed	   0.325	  	   Q10	   0.706	  	   Q35	   0.128	  	   Q104	   0.004	  ZF6xHunt	   Q0	   EGFP	   0.010	  	   Q10	   0.020	  	   Q35	   <0.001	  	   Q104	   <0.001	  	   Q0	   HcRed	   0.158	  	   Q10	   0.468	  	   Q35	   0.540	  	   Q104	   <0.001	  ZF11xHunt	   Q0	   EGFP	   0.157	  	   Q10	   0.046	  	   Q35	   <0.001	  	   Q104	   <0.001	  	   Q0	   HcRed	   0.221	  	   Q10	   0.990	  	   Q35	   0.848	  	   Q104	   0.109	  ZF18xHunt	   Q0	   EGFP	   0.281	  	   Q10	   0.280	  	   Q35	   <0.001	  	   Q104	   <0.001	  	   Q0	   HcRed	   0.090	  	   Q10	   0.437	  	   Q35	   0.077	  	   Q104	   0.023	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Supplementary Table S2. Students’ t-test analysis of the fold repression data against 
an expected value of 1, from the qRT-PCR experiment in Fig. 2D.  
 
 




p-­‐value	  ZF4xHunt	   Q0	   EGFP	   0.005	  	   Q10	   0.915	  	   Q35	   0.004	  	   Q104	   0.009	  	   Q0	   HcRed	   0.282	  	   Q10	   0.207	  	   Q35	   0.444	  	   Q104	   0.644	  ZF6xHunt	   Q0	   EGFP	   0.735	  	   Q10	   0.417	  	   Q35	   0.059	  	   Q104	   0.022	  	   Q0	   HcRed	   0.575	  	   Q10	   0.038	  	   Q35	   0.386	  	   Q104	   0.994	  ZF11xHunt	   Q0	   EGFP	   0.582	  	   Q10	   0.372	  	   Q35	   0.008	  	   Q104	   0.010	  	   Q0	   HcRed	   0.046	  	   Q10	   0.318	  	   Q35	   0.282	  	   Q104	   0.495	  ZF18xHunt	   Q0	   EGFP	   0.145	  	   Q10	   0.340	  	   Q35	   0.004	  	   Q104	   0.053	  	   Q0	   HcRed	   <0.001	  	   Q10	   0.324	  	   Q35	   0.349	  	   Q104	   0.356	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Table S3.  
CAG-repeat number per gene and corresponding primer sets for qRT-PCR. Name 
prefixes: h=human; m=mouse. Approximate CAG repeat number for wild-type genes 
was obtained from Genbank mRNA data. CAG-repeat length: the first number 
corresponds to pure CAG repeats, the second number to broken CAG repeats 






Forward primer Reverse primer 
EGFP 0 - 104 CCTGAAGTTCATCTGCACCA AAGTCGTGCTGCTTCATGTG 
HcRed 0 AGATGCTGCGGAAGAAGAAG GGTACCGTCGACTGCAGAA 
    
hHPRT N/A CTTTGCTTTCCTTGGTCAGG TATCCAACACTTCGTGGGGT 
hATN1 16,22 GTCTCCCTCCGATCTGGATA CACACTTCCAGGGCTGTAGA 
hATXN1 12,29 CCAGCACCGTAGAGAGGATT AGCCCTGTCCAAACACAAA 
hATXN2 13,23 GACGCAGCTGAGCAAGTTAG GAAGGAACGTGGGTTGAACT 
hATXN3 7,14 AGAGCTTCGGAAGAGACGAG ACTCCCAAGTGCTCCTGAAC 
hATXN7 10 AACTGTGTGGCTCACTCTGG TGGGAAGATGTTACCGTTGA 
hCACNA1A 13 GGGAACTACACCCTCCTGAA CGCTGCTTCTTCTTCCTCTT 
hTBP 18,38 ACGCCGAATATAATCCCAAG CTTCACTCTTGGCTCCTGTG 
hHtt 21,23 CAGATGTCAGAATGGTGGCT GCCTTGGAAGATTAGAATCCA  
    
mATN1 3,10 CACCTGCCTCCACCTCATGGC ATGCTCCTTGGGGGCCCTGG 
mATXN1 2 TGTGGAGAGAATCGAGGAGA CAGCCCTGTCCAAATACAAA 
mATXN2 6,10 ATCCCAATGCAAAGGAGTTC CTGCTGATGACCCACCATAG 
mATXN3 5,6 ACCTCGCACTATTCTTGGCT TGCATCTGTTGGACCTTGAT 
mATXN7 5,7 TGCCCGTGTTCCTCACCGGA GCGCGGAGACAGTGGTTGCT 
mCACNA1A 2,3 CACTGGCAATAGCAAAGGAA TTCTTGAGCGAGTTCACCAC 
mTBP 3,13 ACTTCGTGCAAGAAATGCTG GCTCATAGCTCTTGGCTCCT 
mGRK4 N/A TCCTGGCTTTGAGGAGCCGA CCACAGCACAGCTCTGCAGCAT 
mRgs12 N/A GGGGGCTCAAGCAGGCATGG GGGAGCCAGCCTCCGAGTCA 
mHtt 4,7 CAGATGTCAGAATGGTGGCT GCCTTGGAAGATTAGAATCCA  
mHPRT N/A GGTTAAGCAGTACAGCCCCA AGAGGTCCTTTTCACCAGCA 
mActb N/A GCTTCTTTGCAGCTCCTTCGT CCAGCGCAGCGATATCG 
mAtp5b  N/A CCACCGACATGGGCACAATGCA ATGGGCAAAGGTGGTTGCAGGG 	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Table S4. Striatal volume and cell density are not affected by the genotype of mice or 
the treatment applied to the hemisphere (Repeated measures ANOVA, Genotype 
p>0.1; Treatment p>0.1 for both measures). Mean±SEM. 
 	  
 Striatal volume (mm3) 
Cell density in the 
striatum 










WT 4.75±0.21 5.08±0.14 1116.23±90.14 991.92±110.71 
R6/2 4.75±0.33 5.25±0.39 934.92±197.34 985.47±53.26 	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  A 




Figure S1. Comparison of ZF11xHunt and ZF12xHunt in episomal reporter 
repression. Cells were cotransfected with reporter and zinc finger plasmids: the pEH 
reporter plasmid contains EGFP, fused to Q35, under an SV40 promoter. pCMV-
ZFxHunt (CMV promoter) expression constructs contain “naked” chains of ZFxHunt 
(6, 11 or 12 fingers, as indicated). The pTarget vector does not contain ZFP and is 
used as a control. FACS assay measuring the fold-reduction in EGFP fluorescent 
cells, in response to different “naked” zinc fingers (A). A 5-fold repression is 
equivalent to 80% reduction. (B) FLAG Western blot for ZFP expression shows 
similar stability and expression levels for all constructs. β-actin staining is used as a 
loading control.  





Figure S2. Episomal reporter repression by pPGK-ZFxHunt. Cells were cotransfected 
with reporter and zinc finger plasmids: the pEH reporter plasmid contains EGFP, 
fused to different-length poly-Q coding sequences, under an SV40 promoter. A 
control HcRed gene, under a CMV promoter, measures off-target or long-range 
repression. pPGK-ZF (PGK-promoter) expression constructs contain chains of 
ZFxHunt (0 - 18 fingers, as indicated). ZFP are not fused to any effector domain. The 
pTarget vector does not contain ZFP and is used as a control. (A) FACS assay 
measuring the fold-reduction in EGFP or HcRED fluorescent cells, in response to 
different zinc fingers. A 5-fold repression is equivalent to 80% reduction. (B) qRT-
PCR assay to measure fold-repression of EGFP or HcRED mRNA by ZFP.(C) EGFP 
Western blot for ZFP repression of pEH-Qx targets. β-actin staining is used as a 
loading control.  
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Figure S3. Repression of chromosomal CAG-repeat genes, 20 days after retroviral 
ZFP delivery, in homozygous and heterozygous cells. Assays were carried out in wt 
mouse STHdh cells (Q7/Q7), in homozygous poly-Q STHdh mutants (Q111/Q111), 
in heterozygous poly-Q STHdh mutants (Q7/Q111), and in human HEK293T cells, as 
indicated. qRT-PCR was used to compare HTT mRNA levels (mRNA fold-
repression). Mouse primers that do not discriminate between wt or mut HTT were 
used, and consequently, repression of HTT in heterozygous STHdh cells was 
approximately half of that was seen in homozygous mutant STHdh cells, suggesting 
that the levels of repression seen correspond to repression of mutant HTT.  
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Figure S4. ZFxHunt toxicity assay. HEK-293T cells were transfected with 400 ng of 
the indicated vector constructs using Lipofectamine2000 and harvested 48 hours after 
transfection. As a control Lipofectamine2000-only or untransfected cells (negative) 
were used. Cytotoxicity was analyzed using Guava Cell Toxicity (PCA) Assay 
according to manufacturer’s instructions. Results show the percentage of dead mid-
apoptotic and viable cells. Bars express results of at least 3 independent experiments. 
In conclusion, ZFxHunt proteins do not appear to be toxic. 





Figure S5. (A) Western blot of dissected striatum shows expression of GFP in one 
hemisphere and ZF11xHunt-Kox-1 (with FLAG-tag) in the other, corresponding with 
injections. (B) qRT-PCR data quantifying % of mut HTT mRNA vs control 
hemisphere in mouse striatal samples injected with ZF11xHunt-Kox-1 in one 
hemisphere. The other hemisphere was either injected with GFP, n=3 (dark grey) or 
non-injected, n=3 (light gray). Cerebellum was non-injected. There are no 
statistically-significant differences, indicating that the effect observed is due to 
repression by zinc fingers, and not to a toxic effect by GFP. Student's T-test p-values: 
0.18 (striatum) and 0.48 (cerebellum). 




Figure S6. Assaying the cellular targeting of AAV2/1 by immunohistochemistry. (A) 
GFP fluorescence (green) reveals AAV2/1 transduction in a striatal section (scale bar: 
10 µm). (B) Anti-NeuN immunofluorescence (red) marks neuronal cell bodies as 
previously shown in Ref. 37. (C) The merged image reveals AAV2/1 transduction of 
neurons, together with NeuN, showing that transgene expression coincides with a 
neuronal cell marker. It should be noted that while the AAV1 capsid protein does 
have neuronal tropism, it also efficiently transduces most glial and some ependymal 
cells. 
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Figure S7. Quantifying HTT-positive aggregates by automatic counting of mut HTT 
positive particles with ImageJ software, using the method of Moncho-Bogani et al. 
(Neurosci 21(8):2186-2198). (A) Using mut HTT-immunostained coronal slices, a 
region of interest of 650 x 865 µm2, was selected in the middle of the dorsal striatum 
(10X objective). (B) Background was subtracted and the image was converted to 8-
bit. (C) A grey-level histogram was calculated and a threshold of 70% of the mode 
was used for binarization (i.e, leaving particles showing a grey level >30% of the 
mode). (D) The image was filtered with an erosion-dilation filter to eliminate noise 
and the number of remaining particles was automatically counted. Counts were made 
in 4 serial slices, separated by 240 µm, and averaged providing a single density 
measure per hemisphere. Counts were then calculated per 0.1 mm2. 




Figure S8. Anti-HTT immunostaining of the striatum and cortex of R6/2 and wt 
mice. (A) Staining R6/2 striata reveals a reduction of the intensity of mutant 
aggregates with ZF11xHunt-Kox-1 treatment. Data are from three mice (m1, m2 and 
m3) and from four brain sections per mouse (s1-s4). The treated and untreated 
hemispheres are stained simultaneously within each section. Close-ups are shown to 
aid visualisation (see main Fig. 6C for wide-field views). The automated HTT 
counting method used wide-field views (Fig. S7). (B) Sections from wild-type (wt) 
mice are shown for comparison and contain no mut HTT aggregates. Scale bars: 
10µm for R6/2; 100 µm for wt.  
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Figure S9. Weight of R6/2 mice and their WT littermate groups across 3 weeks 
during which the rotarod assay was carried out. An ANOVA of repeated measures 
with Group as between subject factor and Week as within subject factor revealed a 
significant main effect of Week (F2, 47=435, p<0.001) but not of Group (F3, 47=2.41, 
p=0.079). All measures Mean±S.E.M. WT-GFP-treated (n=14), WT- ZF11xHunt-
Kox-1 treated (n=14); R6/2-GFP treated (n=12); R6/2-ZF11xHunt-Kox-1 treated 
(n=12). 
 
